Trials / Completed
CompletedNCT01420809
Special Drug Use Investigation for ARIXTRA® (Fondaparinux) Injection
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,280 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This post-marketing surveillance study was designed to collect and assess the information on proper use of fondaparinux injection, such as the safety and efficacy under actual use conditions, in subjects undergoing orthopedic surgery of the lower limb at high risk of developing venous thromboembolism. (ARIXTRA® is a trademark of the GlaxoSmithKline group of companies.)
Conditions
Timeline
- Start date
- 2007-09-01
- Primary completion
- 2009-05-01
- Completion
- 2009-08-01
- First posted
- 2011-08-22
- Last updated
- 2017-05-16
Source: ClinicalTrials.gov record NCT01420809. Inclusion in this directory is not an endorsement.